The clinical utility of genotypic drug resistance testing (DRT) in HIV-infected children on antiretroviral therapy (ART) is not well understood. HIV-infected patients aged <19 years undergoing DRT for virological failure were retrospectively enrolled. Indications for DRT and changes in HIV RNA load were recorded. Between January 2000 and December 2006, 57 patients had DRT. The most common indication for DRT was poor ART adherence (57.7% of patients). ART was changed in 50.9% of patients after DRT. Poor adherence was cited by clinicians for not changing ART significantly more often than any other reason (47.3%, P < 0.001). After DRT, significant improvement in HIV RNA load occurred independent of ART changes, though patients whose ART was modified were more likely to become undetectable (31.5% versus 7.0%, P < 0.001). Poor adherence was a significant factor for ordering DRT and for not changing ART in HIV-infected children.
DelaugerreCWarszawskiJChaixMPrevalence and risk factors associated with antiretroviral resistance in HIV-1 infected children. J Med Virol2007;79:1261–9
2.
GreenHGibbDMCompagnucciAA Randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial. Antivir Ther2006;11:857–67
3.
LittleSJHolteSRoutyJPAntiretroviral drug resistance among patients recently infected with HIV. N Engl J Med2002;347:385–94
4.
BodenDHurleyAZhangLHIV-1 drug resistance in newly infected individuals. J Am Med Assoc1999;282:1135–41
5.
VianiRMPeraltaLAldrovandiGPrevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis2006;194:1505–9
6.
MensonENWalkerASSharlandMUnderdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study. Br Med J2006;332:1183–7
7.
KingJRKimberlinDWAldrovandiGMAntiretroviral pharmacokinetics in the paediatric population. Clin Pharmacokinet2002;41:1115–33
8.
Van DykeRBLeeSJohnsonGMReported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics2002;109:e61
9.
HannaGJD'AquillaRT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis2001;32:774–82
10.
BrindeiroPABrindeiroRMMortensenCTesting genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol2002;40:4512–9
11.
BadolatoRSchumacherRRodellaEGenotyping for guiding drug choice in human immunodeficiency virus infected children failing multiple antiretroviral treatment regimens. Pediatr Infect Dis J2005;24:747–8
12.
ServaisJHainautMSchmitzVResistance testing in children changing human immunodeficiency virus type 1 protease inhibitor. Pediatr Infect Dis J2002;21:214–20
13.
CohenNJOramRElsenCResponse to changes in antiretroviral therapy after genotyping in human immunodeficiency virus infected children. Pediatr Infect Dis J2002;21:647–53
14.
CaldwellMBOxtobyMJSimondsRJ1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morb Mortal Wkly Rep1994;43:1–10
15.
SchneiderEWhitmoreSGlynnMKRevised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years – United States, 2008. Morb Mortal Wkly Rep2008;57:1–8
16.
JohnsonVABrun-VezinetFClotetBUpdate of the drug resistance mutations in HIV-1: December 2010. Top HIV Med2010;18:156–63
17.
MellinsCABrackis-CottEDolezalCThe role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J2004;23:1035–41
18.
MullenJLeechSO'SheaSAntiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol2002;68:299–304
19.
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. See http://aidsinfo.nih.gov/ContentFiles/Ivguidelines/PediatricGuidelines.pdf August 2011 (last checked 11 June 2012)
20.
DescampsDLambert-NiclotSMarcelinAGMutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother2009;63:585–92
21.
VingerhoetsJTambuyzerLAzijnHResistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS2010;24:503–14
22.
ReumanECRheeSYHolmesSPShaferRW. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Antimicrob Chemother2010;65:1477–85
